肝胆相照论坛

标题: 乙型肝炎核心抑制剂ABI-H0731与核苷酸(t)逆转录酶抑制剂联 [打印本页]

作者: StephenW    时间: 2020-9-25 22:26     标题: 乙型肝炎核心抑制剂ABI-H0731与核苷酸(t)逆转录酶抑制剂联

                                                                                                                                                                                                                                                                                              

                                    Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg negative chronic hepatitis B infection

                                    EASL 2020 virtual Aug 27-29
Reported by Jules Levin

Scott Fung1, Mark S. Sulkowski2, Jacob Lalezari3, Eugene R. Schiff4, Douglas Dieterich5, Tarek Hassanein6, Paul Kwo7, Magdy Elkhashab8, Ronald Nahass9, Walid Ayoub10, Steven-Huy Han11, Maurizio Bonacini3, Katia Alves12, Hany Zayed12, Qi Huang12, Richard Colonno12, Steven J Knox12, Luisa M. Stamm12, Alnoor Ramji13, Michael Bennett14, Edward Gane15, Natarajan Ravendhran16, James Park17, Ira Jacobson17, Ho Bae18, Sing Chan19, Hie-Won Hann20, Xiaoli Ma21, Tuan T. Nguyen22, Man-Fung Yuen23

1University of Toronto, Toronto, Canada; 2Johns Hopkins University School of Medicine, Baltimore, MD, US; 3Quest Clinical Research, San Francisco, CA, US; 4Schiff Center for Liver Diseases, University of Miami School of Medicine, Miami, FL, US; 5Department of Medicine, Division of Liver Diseases, Icahn School of Medicine, Mount Sinai Hospital, New York, NY, US; 6Southern California Research Center, Coronado, CA, US; 7Stanford University Medical Center, Stanford, CA, US; 8Toronto Liver Centre, Toronto, ON, Canada; 9Infectious Disease Care, Hillsborough, FL, US; 10Cedars-Sinai Medical Center, Los Angeles, CA, US; 11Pfleger Liver Institute, Universityof California, Los Angeles, CA, US; 12Assembly Biosciences, Inc., South San Francisco, CA, US; 13Providence Health Care Research Institute, Vancouver, BC, Canada; 14Medical Associates Research Group, San Diego, CA, US; 15Auckland Clinical Studies Ltd, Auckland, New Zealand; 16Digestive Disease Associates, Catonsville, MD, US; 17New York University Langone Medical Center, New York, NY, US; 18Asian Pacific Liver Center, Los Angeles, CA, US; 19Sing Chan MD, New York, NY, US; 20Thomas Jefferson University Hospital, Philadelphia, PA, US; 21Office of Xiaoli Ma, Philadelphia, PA, US; 22T Nguyen Research and Education, Inc., San Diego, CA, US; 23Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong












                                       

作者: windu    时间: 2020-9-26 10:51

有一例出现反弹?什么情况?
作者: 乙肝人1949    时间: 2020-9-26 18:04

啥啥啥,能有翻译不?Pp丅做的不错
作者: StephenW    时间: 2020-9-26 20:07

回复 windu 的帖子

"one patient experienced hbvdna rebound (1 log increase from nadir) in the setting of non-compliance with both study drugs"

一名患者经历了hbvdna反弹(从最低点增加了1 log), 在两种药物均未依从的情况下.
作者: windu    时间: 2020-9-26 20:18

未依从,原谅我没看到,如果这样的话,证明0731的停药理论有可能成功
作者: windu    时间: 2020-9-26 20:22

HBsAg即使缓慢,但能够持续下降,关键是核心抗原HBcrAg也下降,可以期待
作者: windu    时间: 2020-9-26 20:24

停药半年没有反弹,不错
作者: 左罗    时间: 2020-9-27 11:38

windu 发表于 2020-9-26 20:24
停药半年没有反弹,不错

“未依从,原谅我没看到,如果这样的话,证明0731的停药理论有可能成功”

        非常期待这样的神药诞生,继续吧,祝福好运!




欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) Powered by Discuz! X1.5